Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat

PHASE1CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 17, 2018

Primary Completion Date

November 29, 2018

Study Completion Date

February 26, 2019

Conditions
Coronary Artery Disease
Interventions
DRUG

Vericiguat (BAY1021189)

A : 2.5 mg vericiguat A\*: 2.5 mg vericiguat B : 5 mg vericiguat C : 10 mg vericiguat C\*: 10 mg vericiguat

DRUG

Moxifloxacin

D: 400 mg moxifloxacin

DRUG

Placebo

A : vericiguat placebo 10 mg A\*: vericiguat placebo 10 mg + moxifloxacin placebo B : vericiguat placebo 10 mg C : vericiguat placebo 2.5 mg C\*: vericiguat placebo 2.5 mg + moxifloxacin placebo D : vericiguat placebo 2.5 mg + vericiguat placebo 10 mg

Trial Locations (8)

13353

Charité Campus Virchow-Klinikum (CVK), Berlin

14050

PAREXEL GmbH, Berlin

53105

Medizinische Einrichtungen der Universität Bonn, Bonn

69120

Universitätsklinikum Heidelberg, Heidelberg

79189

Universitätsherzzentrum Freiburg - Bad Krozingen, Bad Krozingen

99084

SocraTec R&D Clinical Ward, Erfurt

MD2025

IMSP Republican Clinical Hospital, Chisinau

2333 CL

Center for Human Drug Research, Leiden

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Bayer

INDUSTRY